# Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors

> **NCT04074135** · PHASE2 · RECRUITING · sponsor: **National Cancer Institute (NCI)** · enrollment: 740 (estimated)

## Conditions studied

- VHL Pancreatic Neuroendocrine Tumors
- Von Hippel-Lindau Disease
- Neuroendocrine Tumors

## Interventions

- **DRUG:** 68-Gallium DOTATATE

## Key facts

- **NCT ID:** NCT04074135
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2020-06-02
- **Primary completion:** 2036-01-30
- **Final completion:** 2036-07-01
- **Target enrollment:** 740 (ESTIMATED)
- **Last updated:** 2026-04-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04074135

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04074135, "Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04074135. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*